Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
October 25, 2022 11:15 AM EDT
R&D

No­var­tis toss­es more US PD-1 sub­mis­sion plans and an­oth­er an­ti-CD40 drug in­di­ca­tion

Lei Lei Wu

News Reporter

Buried in No­var­tis’ third quar­ter re­port were a few key in­di­ca­tion drops.

First, No­var­tis is no longer plan­ning to sub­mit tislelizum­ab for FDA ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times